Skip to content
value.today

Codexis, Inc. and its peers

1 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.

Companies in the group

Up to 12. Remove or re-base from the table's column heads.

Also: these companies in the compare tool.

Keep this group

Save it for yourself or, in a team, for everyone in it.

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Perspective Therapeutics, Inc.CATX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $141 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $141 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $144 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Compass Therapeutics, Inc.CMPX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $137 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $137 M (Oct 29, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • TuHURA Biosciences, Inc. NVHURA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $135 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $135 M (Oct 30, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Voyager Therapeutics, Inc.VYGR · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $134 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $134 M (Oct 14, 2026) · revenue $40 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Armata Pharmaceuticals, Inc.ARMP · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $130 M (Oct 28, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Spruce Biosciences, Inc.SPRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $130 M (Oct 26, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Sutro Biopharma, Inc.STRO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $155 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $155 M (Oct 26, 2026) · revenue $102 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Nkarta, Inc.NKTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125 M (Oct 22, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Humacyte, Inc.HUMA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $125 M (Oct 28, 2026) · revenue $2 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Anavex Life Sciences Corp.AVXL · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $123 M (Oct 26, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Foghorn Therapeutics Inc.FHTX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Codexis, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCodexis, Inc.base
CDXS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$140 MOct 26, 2026 · Market dataonly one with it$140 M—
Revenue (Better neither way: ranked highest first)$70 MFY2025 · SEConly one with it$70 M—
Net income (Higher is better)$-44 MFY2025 · SEConly one with it$-44 M—
Employees (Better neither way: ranked highest first)261As on 2021 · Profileonly one with it261—
Growth
Revenue growth (Higher is better)+18.6%FY2025 · SEConly one with it66th77th+18.6%—
Revenue growth, 3 years a year (Higher is better)-20.2%FY2025 · SEConly one with it6th4th-20.2%—
Margins and returns
Gross margin (Higher is better)86.7%FY2025 · SEConly one with it88th95th86.7%—
Operating margin (Higher is better)-59.3%FY2025 · SEConly one with it29th14th-59.3%—
Net margin (Higher is better)-62.5%FY2025 · SEConly one with it28th13th-62.5%—
Free cash flow margin (Higher is better)-33.9%FY2025 · SEConly one with it31st14th-33.9%—
Return on equity (Higher is better)-74.9%FY2025 · SEConly one with it32nd13th-74.9%—
Valuation
Price to sales (Better neither way: ranked highest first)1.6×price Oct 26, 2026 · Market dataonly one with it27th41st1.6×—
Price to book (Better neither way: ranked highest first)2.8×price Oct 26, 2026 · Market dataonly one with it47th59th2.8×—
Free cash flow yield (Higher is better)-17.0%price Oct 26, 2026 · Market dataonly one with it35th16th-17.0%—
Financial strength
Debt to equity (Lower is better)0.8×FY2025 · SEConly one with it69th60th0.8×—
Piotroski F-score (Higher is better)4 of 9FY2025 · SEConly one with it4.0 of 9—
Scorecard
Scorecard (Higher is better)7 of 22FY2025 · Scorecardonly one with it32% passed—
Valuation checks (Higher is better)2 of 5FY2025 · Scorecardonly one with it40% passed—
Growth checks (Higher is better)1 of 6FY2025 · Scorecardonly one with it17% passed—
Profitability checks (Higher is better)1 of 5FY2025 · Scorecardonly one with it20% passed—
Financial health checks (Higher is better)3 of 5FY2025 · Scorecardonly one with it60% passed—
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecardonly one with it0% passed—
Ownership
Held by institutions (Better neither way: ranked highest first)68.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it68.6%—
Institutions holding (Better neither way: ranked highest first)1302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it130—
Institutional holding, change over the quarter (Better neither way: ranked highest first)-8.3 pp2026-Q2 against 2026-Q1 · 13Fonly one with it-8.3 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Codexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Codexis, Inc.-59.3%FY2025
29th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$35 M$69 M$104 M$139 M20102012201420162018202020222024Codexis, Inc. $70 M

Rank in the group

Ranks need two fiscal years with the figure for at least two of these companies.

Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCodexis, Inc.
2025$70 MSEC
2024$59 MSEC
2023$70 MSEC
2022$139 MSEC
2021$105 MSEC
2020$69 MSEC
2019$68 MSEC
2018$61 MSEC
2017$50 MSEC
2016$49 MSEC
2015$42 MSEC
2014$35 MSEC

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.